Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of RHB-104 versus placebo in moderate to severe active Crohn's disease
MOH_2017-02-15_000077Phase 3Completed
- Sponsor
- RedHill Biopharma
- Start
- Aug 2013
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of RHB-104, clarithromycin, rifabutin and clofazimine in Crohn's disease (2 arms), sponsored by RedHill Biopharma. Started Aug 2013; status: completed.
02
Drugs
RHB-104clarithromycinrifabutinclofazimine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2017-02-15_000077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-15_000077.